# US 2015/0105288 A1 · Genetically modified non-human animals and methods relating to innate immune system response detection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105288 A1
- Document ID: US20150105288A1
- Status: Published application
- Kind: A1
- Application number: 14/511,793
- Filed: 2014-10-10
- Published: 2015-04-16
- Earliest claimed: 2013-10-11
- Assignees: The Jackson Laboratory; University of Massachusetts
- Applicants: The Jackson Laboratory; University of Massachusetts
- Inventors: Leonard D. Shultz; Dale L. Greiner; Michael A. Brehm
- Web page: https://patentgrep.com/patent/US20150105288A1

## CPC

- A01K 67/0276: Knock-out vertebrates
- A01K 67/0271: Chimeric vertebrates, e.g. comprising exogenous cells
- G01N 33/5023: {on expression patterns}
- G01N 33/5088: {of vertebrates}
- A01K 2207/12: Animals modified by administration of exogenous cells
- A01K 2207/20: Animals treated with compounds which are neither proteins nor nucleic acids
- A01K 2217/056: due to mutation of coding region of the transgene (dominant negative)
- A01K 2217/15: Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
- A01K 2227/105: Murine
- A01K 2267/03: Animal model, e.g. for test or diseases
- A01K 2267/0387: Animal model for diseases of the immune system
- G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Described herein are immunodeficient non-human animals lacking expression of toll-like receptor 4 (TLR4) by endogenous autogeneic innate immune cells, as well as methods and compositions for engraftment of xenogeneic hematopoietic stem cells in the immunodeficient non-human animal lacking expression of toll-like receptor 4 (TLR4), thereby creating an innate immune system in the animal derived from the xenogeneic hematopoietic stem cells. Further described are immunodeficient mice lacking expression of toll-like receptor 4 by endogenous autogeneic innate immune cells, as well as methods and compositions for engraftment of xenogeneic hematopoietic stem cells in the immunodeficient mouse lacking expression of toll-like receptor 4, thereby creating an innate immune system in the animal derived from the xenogeneic hematopoietic stem cells.

## Claims

### Claim 1

A genetically modified immunodeficient non-human animal, wherein the genome of the non-human animal comprises a disrupted toll-like receptor 4 gene such that the non-human animal lacks the capacity to express the toll-like receptor 4 gene.

### Claim 2 (depends on 1)

The genetically modified immunodeficient non-human animal of claim 1 wherein the animal has severe combined immunodeficiency.

### Claim 3 (depends on 1)

The genetically modified immunodeficient non-human animal of claim 1 wherein the animal has an IL2 receptor gamma chain deficiency.

### Claim 4 (depends on 1)

The genetically modified immunodeficient non-human animal of claim 1, wherein the animal is a mouse.

### Claim 5 (depends on 4)

The genetically modified immunodeficient non-human animal of claim 4, wherein the mouse comprises the scid mutation.

### Claim 6 (depends on 5)

The genetically modified immunodeficient non-human animal of claim 5, wherein the mouse is homozygous for the scid mutation.

### Claim 7 (depends on 1)

The genetically modified immunodeficient non-human animal of claim 1, wherein the genetically modified immunodeficient animal is a NOD.Cg-Prkdcscid Il2rgtml Wjl/SzJ mouse comprising a disrupted toll-like receptor 4 gene such that the non-human animal lacks the capacity to express the toll-like receptor 4 gene.

### Claim 8 (depends on 1)

The genetically modified immunodeficient non-human animal of claim 1, further comprising xenogeneic haematopoietic stern cells.

### Claim 9 (depends on 1)

The genetically modified immunodeficient non-human animal of claim 1, further comprising human haematopoietic stem cells.

### Claim 10 (depends on 1)

The genetically modified immunodeficient non-human animal of claim 1, further comprising xenogeneic innate immune cells.

### Claim 11 (depends on 1)

The genetically modified immunodeficient non-human animal of claim 1, further comprising human innate immune cells.

### Claim 12

A method for producing a non-human animal model system for response of xenogeneic innate immune cells, comprising:
providing a non-human genetically modified immunodeficient animal comprising a disrupted toll-like receptor 4 gene such that the non-human genetically modified immunodeficient animal lacks the capacity to express the toll-like receptor 4 gene; and
administering xenogeneic haematopoietic stem cells to the non-human genetically modified immunodeficient animal.

### Claim 13 (depends on 12)

The method of claim 12, wherein the non-human genetically modified immunodeficient animal has severe combined immunodeficiency.

### Claim 14 (depends on 12)

The method of claim 12, wherein the non-human genetically modified immunodeficient animal has an IL2 receptor gamma chain deficiency.

### Claim 15 (depends on 12)

The method of claim 12, wherein the non-human genetically modified immunodeficient animal is a mouse.

### Claim 16 (depends on 15)

The method of claim 15, wherein the mouse comprises the scid mutation.

### Claim 17 (depends on 16)

The method of claim 16, wherein the mouse is homozygous for the scid mutation.

### Claim 18 (depends on 12)

The method of claim 12, wherein the genetically modified immunodeficient animal is a NOD.Cg-Prkdcscid Il2rgtml Wjl/SzJ mouse comprising a disrupted toll-like receptor 4 gene such that the mouse lacks the capacity to express the toll-like receptor 4 gene.

### Claim 19 (depends on 12)

The method of claim 12, wherein the xenogeneic haematopoietic stem cells are human haematopoietic stem cells.

### Claim 20

A method for identifying modulators of an innate immune system response, comprising:
providing a non-human genetically modified immunodeficient animal comprising a disrupted toll-like receptor 4 gene such that the non-human genetically modified immunodeficient animal lacks the capacity to express the toll-like receptor 4 gene;
administering xenogeneic haematopoietic stem cells to the non-human genetically modified immunodeficient animal, wherein the xenogeneic haematopoietic stem cells differentiate to produce xenogeneic innate immune cells in the non-human genetically modified immunodeficient animal;
administering an innate immune system stimulator to the animal;
administering a test compound to the animal;
assaying a response of the xenogeneic innate immune cells to the stimulator; and
comparing the response to a standard to determine the effect of the test compound on the response of the xenogeneic innate immune cells to the stimulator, wherein an effect of the test compound identifies a modulator of the xenogeneic innate immune system in the animal.
